Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer

To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.

Participants needed: 32
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Beihua KongUpdated: Sep 4, 2025
Eligibility criteria

Women over 18 years old; [+8]

Have had other malignant tumors within the last five years; [+6]

Read more
Status: Recruiting

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery.

Participants needed: 129
Trial details
Phase: Phase 3Age: 14-65Biological sex: FemaleType: InterventionalSponsor: Beihua KongUpdated: Apr 25, 2023Locations: 1
Eligibility criteria

Age≤65 years; female, Chinese women; [+13]

With severe or uncontrolled internal disease, unable to receive surgery and/or u... [+7]

Read more
Status: Recruiting

TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors

Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed ovarian malignant sex cord-stromal tumor patients after surgery.

Participants needed: 132
Trial details
Phase: Phase 3Age: 14-65Biological sex: FemaleType: InterventionalSponsor: Beihua KongUpdated: Apr 25, 2023Locations: 1
Eligibility criteria

Age≤65 years; female, Chinese women; [+13]

With severe or uncontrolled internal disease, unable to receive surgery and/or u... [+7]

Read more